drugset / Trial / NCT05822453
Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).
Timeline
- Start
- 2023-04-30
- Primary completion
- 2025-04-30
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 60 mg | Oral |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |